Knight Therapeutics (KHTRF)
OTHER OTC:KHTRF
KHTRF Stock Chart & Stats
$5.36
-$0.05(-1.39%)
At close: 4:00 PM EST
$5.36
-$0.05(-1.39%)
Day’s Range― - ―
52-Week Range$3.88 - $5.36
Previous CloseN/A
Volume100.00
Average Volume (3M)896.00
Market Cap
$524.51M
Enterprise Value$741.17M
Total Cash (Recent Filing)$95.28M
Total Debt (Recent Filing)$77.91M
Price to Earnings (P/E)―
Beta-0.04
Next Earnings
May 07, 2026EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.06
Shares Outstanding98,034,744
10 Day Avg. Volume1,740
30 Day Avg. Volume896
Financial Highlights & Ratios
PEG Ratio0.50
Price to Book (P/B)0.79
Price to Sales (P/S)1.34
P/FCF Ratio8.81
Enterprise Value/Market Cap1.41
Enterprise Value/Revenue1.65
Enterprise Value/Gross Profit4.34
Enterprise Value/Ebitda14.43
Forecast
1Y Price Target
$6.47Price Target Upside20.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.13
Revenue Forecast (FY)$352.54M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetA very low debt load and sizeable equity base give Knight durable financial flexibility to absorb earnings swings, fund in‑licensing or M&A and honor contingencies. This structural strength reduces refinancing risk and preserves optionality for strategic portfolio investments over months.
Improving Cash GenerationMaterial improvement in operating and free cash flow increases self‑funding capacity for product launches, working capital and licensing payments without relying on dilution or heavy borrowing. Sustained cash conversion supports durable investment in commercialization and margin stability.
Portfolio Expansion Driving RevenueRecent in‑licensing and acquisitions (Paladin, Sumitomo) plus oncology additions expanded the marketed portfolio, producing record revenue and higher EBITDA. A broader product mix and new launches in multiple territories strengthen structural revenue sources and lower single‑product dependence.
Bears Say
Earnings VolatilityRepeated swings between profit and loss indicate fragile operating leverage and unpredictable bottom‑line performance. This undermines the company’s ability to reliably fund growth, pay down capital, or deliver consistent returns, increasing long‑term execution risk.
Regulatory SetbacksA formal rejection in Brazil and extended appeal timelines delay access to a large market, compress near‑term revenue potential and raise the cost and timeline of commercialization. Regulatory friction is a persistent operational risk for a company reliant on in‑licensed approvals.
Strategic Investment VolatilityExposure to liquid strategic investments creates earnings and balance sheet volatility via mark‑to‑market swings. Such volatility can obscure core operating performance, risk usable cash in downturns and impose additional management bandwidth to monitor non‑core asset risks.
Knight Therapeutics News
KHTRF FAQ
What was Knight Therapeutics’s price range in the past 12 months?
Knight Therapeutics lowest stock price was $3.88 and its highest was $5.36 in the past 12 months.
What is Knight Therapeutics’s market cap?
Knight Therapeutics’s market cap is $524.51M.
When is Knight Therapeutics’s upcoming earnings report date?
Knight Therapeutics’s upcoming earnings report date is May 07, 2026 which is in 34 days.
How were Knight Therapeutics’s earnings last quarter?
Knight Therapeutics released its earnings results on Mar 19, 2026. The company reported $0.065 earnings per share for the quarter, beating the consensus estimate of -$0.003 by $0.068.
Is Knight Therapeutics overvalued?
According to Wall Street analysts Knight Therapeutics’s price is currently Undervalued.
Does Knight Therapeutics pay dividends?
Knight Therapeutics does not currently pay dividends.
What is Knight Therapeutics’s EPS estimate?
Knight Therapeutics’s EPS estimate is 0.02.
How many shares outstanding does Knight Therapeutics have?
Knight Therapeutics has 98,034,744 shares outstanding.
What happened to Knight Therapeutics’s price movement after its last earnings report?
Knight Therapeutics reported an EPS of $0.065 in its last earnings report, beating expectations of -$0.003. Following the earnings report the stock price went up 0.468%.
Which hedge fund is a major shareholder of Knight Therapeutics?
Currently, no hedge funds are holding shares in KHTRF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Knight Therapeutics
Knight Therapeutics Inc., a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada, Latin America, and internationally. It offers Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib to treat metastatic cholangiocarcinoma; Trelstar for advanced prostate cancer and for pain associated with endometriosis; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic adenocarcinoma; Halaven for metastatic breast cancer and doft tissue sarcoma; and Lenvima for differentiated thyroid cancer, advanced renal cell cancer, and unresectable hepatocellular carcinoma. The company also provides Ladevina for multiple myeloma, myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Exelon for mild to moderately severe dementia; and Ibsrela for the treatment of irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk to treat biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for moderate to severe vasomotor symptoms associated with menopause in women with intact uteri; Fibridoner to treat idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection in patients with cystic fibrosis; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, the company finances other life science companies; and invests in life sciences venture capital funds. Knight Therapeutics Inc. was incorporated in 2013 and is headquartered in Montreal, Canada.
KHTRF Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Knight Therapeutics reported strong financial performance with record revenues and EBITDA, significant growth driven by key products, and an improved financial outlook for 2025. The expansion of the oncology portfolio and increased credit facility provide a solid foundation for future growth. However, challenges were noted with regulatory setbacks in Brazil and Canada and a financial asset loss, though these do not overshadow the overall positive trends and achievements.View all KHTRF earnings summariesKHTRF Stock 12 Month Forecast
Average Price Target
$6.47
▲(20.71% Upside)
Technical Analysis
Cipher Pharmaceuticals
―
Organigram Global
―
Aurora Cannabis
―
Cronos Group
―
HLS Therapeutics Inc
―
Ownership Overview
23.18% Insiders
3.69% Mutual Funds
0.09% Other Institutional Investors
72.32% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---